Upregulation of osteoprotegerin expression correlates with bone invasion and predicts poor clinical outcome in oral cancer

Oral Oncology

Volumn 51, Issue 3, 2015, Pages 247-253

  Russmueller, G ^a   Moser, D ^a   Wurger T ^a   Wrba, F ^a   Christopoulos, P ^b   Kostakis, G ^b   Seemann, R ^a   Stadler, V ^a   Wimmer, G ^a   Kornek, G ^a   Psyrri, A ^c   Filipits, M ^d   Perisanidis, C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ATHENS   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Neoadjuvant therapy; Oral cancer; Osteoprotegerin; Prognosis; RANK ligand; Receptor activator of nuclear factor kappa B

Indexed keywords

ANTINEOPLASTIC AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PERINEURAL INVASION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR BIOPSY; UPREGULATION; BONE NEOPLASMS; CARCINOMA, SQUAMOUS CELL; METABOLISM; MOUTH NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS;

BIOMARKERS, TUMOR; BONE NEOPLASMS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MALE; MOUTH NEOPLASMS; OSTEOPROTEGERIN; PROGNOSIS; RANK LIGAND; SURVIVAL ANALYSIS;

EID: 84923116979     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.11.010     Document Type: Article

References (40)

1. S. Warnakulasuriya Global epidemiology of oral and oropharyngeal cancer Oral Oncol 45 2009 309 316
2. M. Rauner, W. Sipos, and P. Pietschmann Osteoimmunology Int Arch Allergy Immunol 143 2007 31 48
3. S. Theoleyre, Y. Wittrant, S.K. Tat, Y. Fortun, F. Redini, and D. Heymann The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling Cytokine Growth Factor Rev 15 2004 457 475
4. X. Luan, Q. Lu, Y. Jiang, S. Zhang, Q. Wang, and H. Yuan Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin J Immunol 189 2012 245 252
5. W.S. Simonet, D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, and R. Luthy Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319
6. D. Santini, G. Schiavon, B. Vincenzi, L. Gaeta, F. Pantano, and A. Russo Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients PLoS One 6 2011 e19234
7. G. Chen, K. Sircar, A. Aprikian, A. Potti, D. Goltzman, and S.A. Rabbani Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation Cancer 107 2006 289 298
8. S. Tsukamoto, T. Ishikawa, S. Iida, M. Ishiguro, K. Mogushi, and H. Mizushima Clinical significance of osteoprotegerin expression in human colorectal cancer Clin Cancer Res 17 2011 2444 2450
9. X. Peng, W. Guo, T. Ren, Z. Lou, X. Lu, and S. Zhang Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer PLoS One 8 2013 e58361
10. G. Levidou, I. Thymara, A.A. Saetta, P. Papanastasiou, P. Pavlopoulos, and S. Sakellariou TRAIL and osteoprotegerin (OPG) expression in bladder urothelial carcinoma: correlation with clinicopathological parameters and prognosis Pathology 45 2013 138 144
11. R. Ito, H. Nakayama, K. Yoshida, K. Kuraoka, J. Motoshita, and N. Oda Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma Virchows Arch 443 2003 146 151
12. T.A. Guise, K.S. Mohammad, G. Clines, E.G. Stebbins, D.H. Wong, and L.S. Higgins Basic mechanisms responsible for osteolytic and osteoblastic bone metastases Clin Cancer Res 12 2006 12:6213s-6s
13. X. Zhang, C.R. Junior, M. Liu, F. Li, N.J. D'Silva, and K.L. Kirkwood Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss Oral Oncol 49 2013 119 128
14. B.A. Gartrell, and F. Saad Managing bone metastases and reducing skeletal related events in prostate cancer Nat Rev Clin Oncol 11 2014 335 345
15. M. Tsubaki, M. Komai, S. Fujimoto, T. Itoh, M. Imano, and K. Sakamoto Activation of NF-kappaB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines J Exp Clin Cancer Res 32 2013 62
16. E. Pectasides, T. Rampias, C. Sasaki, C. Perisanidis, V. Kouloulias, and B. Burtness Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC) PLoS One 9 2014 e94273
17. D. Lane, I. Matte, C. Laplante, P. Garde-Granger, C. Rancourt, and A. Piche Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis J Ovarian Res 6 2013 82
18. E.N. De Toni, S.E. Thieme, A. Herbst, A. Behrens, P. Stieber, and A. Jung OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer Clin Cancer Res 14 2008 4713 4718
19. T. Tada, E. Jimi, M. Okamoto, S. Ozeki, and K. Okabe Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts Int J Cancer 116 2005 253 262
20. C.K. Martin, W.P. Dirksen, S.T. Shu, J.L. Werbeck, N.K. Thudi, and M. Yamaguchi Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma Oral Oncol 48 2012 491 499
21. N. Cui, T. Nomura, H. Noma, K. Yokoo, R. Takagi, and S. Hashimoto Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice Clin Cancer Res 11 2005 2713 2719
22. F.H. Chuang, S.S. Hsue, C.W. Wu, and Y.K. Chen Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma J Oral Pathol Med 38 2009 753 758
23. T. Honami, T. Shimo, T. Okui, N. Kurio, N.M. Hassan, and M. Iwamoto Sonic hedgehog signaling promotes growth of oral squamous cell carcinoma cells associated with bone destruction Oral Oncol 48 2012 49 55
24. E. Jimi, H. Furuta, K. Matsuo, K. Tominaga, T. Takahashi, and O. Nakanishi The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma Oral Dis 17 2011 462 468
25. K. Sato, J.W. Lee, K. Sakamoto, T. Iimura, K. Kayamori, and H. Yasuda RANKL synthesized by both stromal cells and cancer cells plays a crucial role in osteoclastic bone resorption induced by oral cancer Am J Pathol 182 2013 1890 1899
26. Grimm M, Renz C, Munz A, Hoefert S, Krimmel M, Reinert S. Co-expression of CD44+/RANKL+ tumor cells in the carcinogenesis of oral squamous cell carcinoma. Odontology; 2013.
27. N. Cui, T. Nomura, N. Takano, E. Wang, W. Zhang, and T. Onda Osteoclast-related cytokines from biopsy specimens predict mandibular invasion by oral squamous cell carcinoma Exp Ther Med 1 2010 755 760
28. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 2005 1180 1184
29. L.H. Sobin, and C. Wittekind UICC TNM classification of malignant tumors 7th ed. 2010 Springer Berlin
30. O.M. Braun, B. Neumeister, W. Popp, R. Scherrer, E. Dobrowsky, and W. Dobrowsky Histologic tumor regression grades in squamous cell carcinoma of the head and neck after preoperative radiochemotherapy Cancer 63 1989 1097 1100
31. C. Perisanidis, F. Wrba, A. Brandstetter, G. Kornek, D. Mitchell, and R. Seemann Impact of epidermal growth factor receptor, mesenchymal-epithelial transition factor, and insulin-like growth factor receptor 1 expression on survival of patients with oral and oropharyngeal cancer Br J Oral Maxillofac Surg 51 2013 234 240
32. R. Pirker, J.R. Pereira, J. von Pawel, M. Krzakowski, R. Ramlau, and K. Park EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Lancet Oncol 13 2012 33 42
33. C.M. Shipman, and P.I. Croucher Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells Cancer Res 63 2003 912 916
34. A. Psyrri, V. Kotoula, E. Fountzilas, Z. Alexopoulou, M. Bobos, and D. Televantou Prognostic significance of the Wnt pathway in squamous cell laryngeal cancer Oral Oncol 50 2014 298 305
35. C. Perisanidis, I. Sulzbacher, M. Mittlbock, D. Mitchell, C. Czembirek, and R. Seemann Survival of patients with pathologic T0N+ oral and oropharyngeal cancer after neoadjuvant therapy and surgery: the minority report Oral Surg Oral Med Oral Pathol Oral Radiol 115 2013 293 298
36. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
37. R.W. Johnstone, A.J. Frew, and M.J. Smyth The TRAIL apoptotic pathway in cancer onset, progression and therapy Nat Rev Cancer 8 2008 782 798
38. M. Croft, C.A. Benedict, and C.F. Ware Clinical targeting of the TNF and TNFR superfamilies Nat Rev Drug Discov 12 2013 147 168
39. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, and E. Gronroos Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892
40. E.A. Mroz, and J.W. Rocco MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma Oral Oncol 49 2013 211 215